Laboratory testing in rheumatoid arthritis patients taking disease‐modifying antirheumatic drugs: Clinical evaluation and cost analysis

Abstract

Laboratory tests can be reduced substantially in patients receiving DMARD therapy. In consequence, costs can decrease significantly without oversight of adverse events.